BGI Genomics and Roche Diagnostics launch blood based Alzheimer tests across Chinese cities
BGI Genomics and Roche Diagnostics have launched blood-based Alzheimer's tests in China. The non-invasive tools improve access to newly approved treatments.
Insights:
BGI Genomics Co Ltd and Roche Holding AG have initiated the deployment of blood-based diagnostic tests for Alzheimer’s disease across multiple regions in China 
CN. This development represents the first large-scale availability of non-invasive diagnostics in the world’s second-largest healthcare market. By introducing these tools, the companies aim to address a critical clinical need for easier-to-use diagnosis and monitoring options for an aging population.
CN. This development represents the first large-scale availability of non-invasive diagnostics in the world’s second-largest healthcare market. By introducing these tools, the companies aim to address a critical clinical need for easier-to-use diagnosis and monitoring options for an aging population.BGI Genomics Co Ltdhas successfully placed its diagnostic test into clinical use in the cities of Guangzhou, Qingdao, Shenzhen, and Wuhan. These tests are being utilized to evaluate disease progression and the risk of onset in patients. Simultaneously, Roche Holding AG, headquartered in Switzerland 
CH, has deployed its pTau181 blood test in Boao, Hainan province. Clinical use of the Roche test has already commenced at a hospital in the region, marking a shift toward more accessible biomarker testing.
CH, has deployed its pTau181 blood test in Boao, Hainan province. Clinical use of the Roche test has already commenced at a hospital in the region, marking a shift toward more accessible biomarker testing.
